NewLimit, a longevity biotechnology company co-founded by Coinbase CEO Brian Armstrong, has raised $435 million in a Series C funding round led by Founders Fund. New investors, including Thrive Capital, Greenoaks and Quiet Capital, joined existing backers such as Kleiner Perkins and Eli Lilly Ventures. The company develops age-reprogramming therapies designed to restore cell function affected by aging. The funding will support research and development as NewLimit prepares to move its first drug candidate into human clinical trials next year. The milestone marks a significant step toward testing its technology in patients.
Story Highlights The live price of the CHILLGUY is . CHILLGUY memecoin, inspired by the…
Ethereum co-founder Vitalik Buterin has rejected a prediction from Silicon Valley investor Liron Shapira that…
The XRP holder base has grown significantly over the past few years, changing the amount…
TAO price has turned sharply higher after spending weeks under pressure, with the token climbing…
Senator Cynthia Lummis warned that failure to pass the CLARITY Act in the current Congress…
Katherine Kirkpatrick Bos, Head of Legal at Chainlink, offered a stark assessment of the Clarity…
